Ownership Submission
FORM 3
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  AYRES JOHN C
 2. Date of Event Requiring Statement (Month/Day/Year)
01/04/2019		 3. Issuer Name and Ticker or Trading Symbol
ARATANA THERAPEUTICS, INC. [PETX]
(Last)
(First)
(Middle)
C/O ARATANA THERAPEUTICS, INC., 11400 TOMAHAWK CREEK PARKWAY, SUITE 340		 4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
SEE REMARKS
 5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)

LEAWOOD, KS 66211		 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		 2. Amount of Securities Beneficially Owned
(Instr. 4)		 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		 4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock 98,091
D
 

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)		 2. Date Exercisable and Expiration Date
(Month/Day/Year)		 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		 6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy)   (1) 11/12/2023 Common Stock 66,667 $ 20.4 D  
Stock Option (Right to Buy)   (2) 01/12/2024 Common Stock 20,000 $ 18.42 D  
Stock Option (Right to Buy)   (3) 01/28/2025 Common Stock 25,000 $ 17.18 D  
Stock Option (Right to Buy)   (4) 01/21/2026 Common Stock 70,000 $ 3.14 D  
Stock Option (Right to Buy)   (5) 01/12/2027 Common Stock 37,500 $ 8.02 D  
Stock Option (Right to Buy)   (6) 01/24/2028 Common Stock 60,000 $ 4.83 D  

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
AYRES JOHN C
C/O ARATANA THERAPEUTICS, INC.
11400 TOMAHAWK CREEK PARKWAY, SUITE 340
LEAWOOD, KS 66211		       SEE REMARKS  

Signatures

/s/ John C. Ayres 01/09/2019
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Fully vested as of November 13, 2017.
(2) Fully vested as of January 13, 2018.
(3) Vested as to 25% of the total number of shares (rounded down to the nearest whole share) on January 29, 2016 and vested or will vest, as applicable, as to an additional 1/48th of the total number of shares (rounded down to the nearest whole share) on the same day of each of the 36 successive calendar months thereafter, such that the stock option shall be vested as to all shares on January 29, 2019, subject to continued service with the Issuer through the applicable vesting dates.
(4) Vested as to 25% of the total number of shares (rounded down to the nearest whole share) on January 29, 2017 and vested or will vest, as applicable, as to an additional 1/48th of the total number of shares (rounded down to the nearest whole share) on the same day of each of the 36 successive calendar months thereafter, such that the stock option shall be vested as to all shares on January 29, 2020, subject to continued service with the Issuer through the applicable vesting dates.
(5) Vested as to 25% of the total number of shares (rounded down to the nearest whole share) on January 29, 2018 and vested or will vest, as applicable, as to an additional 1/48th of the total number of shares (rounded down to the nearest whole share) on the same day of each of the 36 successive calendar months thereafter, such that the stock option shall be vested as to all shares on January 29, 2021, subject to continued service with the Issuer through the applicable vesting dates.
(6) Vests as to 25% of the total number of shares (rounded down to the nearest whole share) on January 29, 2019 and as to an additional 1/48th of the total number of shares (rounded down to the nearest whole share) on the same day of each of the 36 successive calendar months thereafter, such that the stock option shall be vested as to all shares on January 29, 2022, subject to continued service with the Issuer through the applicable vesting dates.
 
Remarks:
The Reporting Person is VP - Corporate Operations, General Counsel and Secretary.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.